Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Genes|July 2, 2021
The <i>TNFRSF13C</i> H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern ItalyRoberta Russo, Immacolata Andolfo, Vito Alessandro Lasorsa, et al.
Medicina (Kaunas, Lithuania)|November 11, 2022
Perioperative Red Cell Line Trend following Robot-Assisted Radical Prostatectomy for Prostate CancerFrancesco Di Bello, Ernesto Di Mauro, Claudia Collà Ruvolo, et al.
Journal of Clinical Medicine|April 3, 2021
Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 OutbreakAntonio Carotenuto, Cristiano Scandurra, Teresa Costabile, et al.
Nature Medicine|June 24, 2018
Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisLuigina Romani, Vasilis Oikonomou, Silvia Moretti, et al.
Human Molecular Genetics|May 6, 2014
Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotypeElena Ambrosini, Federico Sicca, Maria S Brignone, et al.
Nature Medicine|June 24, 2018
Publisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisLuigina Romani, Vasilis Oikonomou, Silvia Moretti, et al.
International Journal of Molecular Sciences|June 2, 2021
Regulatory Noncoding and Predicted Pathogenic Coding Variants of <i>CCR5</i> Predispose to Severe COVID-19Sueva Cantalupo, Vito Alessandro Lasorsa, Roberta Russo, et al.
Nature Medicine|April 11, 2017
Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisLuigina Romani, Vasilis Oikonomou, Silvia Moretti, et al.
Journal of Neurology|August 23, 2024
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimodAntonio Carotenuto, Cristina Di Monaco, Laura Papetti, et al.
Intensive Care Medicine|June 2, 2026
Personalized automatic management of tracheal cuff pressure and subglottic secretions drainage to prevent pneumonia in critically ill intubated patients. The MICROINHALO multicenter randomized controlled trialGennaro De Pascale, Salvatore Lucio Cutuli, Maria Vargas, et al.
Pageof 17